Share Email Print

Proceedings Paper

Bioconjugated gold nanoparticles as a contrast agent for optoacoustic detection of small tumors
Author(s): Mohammad A. Eghtedari; John A. Copland; Vsevolod L. Popov; Nicholas A. Kotov; Massoud Motamedi; Alexander A. Oraevsky
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Optoacoustic tomography (OAT) is a medical imaging method for detection of cancerous tumors that uses laser pulses to produce transi ultrasonic waves with spatial profiles replicating distribution of absorbed optical energy. Unlike conventional ultrasonography that uses an external source of acoustic waves, OAT uses transient acoustic waves generated as result of thermal expansion of tissue preferentially heated with short laser pulses. Tissues with different optical properties have different optoacoustic profiles and this enables reconstruction of an acoustic image based on distribution of optical absorption. It is anticipated that the difference in optical absorption between very early tumors and normal tissues might be minimal, justifying application of a contrast agent. Gold Nanoparticles (NP) can be designed to strongly absorb desirable color of laser pulses and effectively produce acoustic waves. Therefore, gold NP can be potentially employed as an optoacoustic contrast agent. We studied sensitivity of optoacoustic imaging in phantoms resembling dimensions and properties of the breast with small objects loaded with gold NPs of various concentrations. Targeted selective loading of breast cancer cells in culture with 40-nm diameter NPs was experimentally demonstrated with electron microscopy and fluorescence labeling techniques. To achieve selective targeting, Herceptin, a monoclonal antibody raised against Her2 receptor was conjugated to NPs using streptavidin-biotin conjugation as a linker. Targeting experiments simultaneously demonstrated that Mab/NPs conjugates inhibit cell proliferation of Her/neu positive cells. These data present the first step in development of a new technology for highly selective cancer chemotherapy with capability to diagnose the presence of malignant tumors and monitor the effects of the treatment.

Paper Details

Date Published: 1 July 2003
PDF: 10 pages
Proc. SPIE 4960, Biomedical Optoacoustics IV, (1 July 2003); doi: 10.1117/12.503617
Show Author Affiliations
Mohammad A. Eghtedari, Univ. of Texas Medical Branch at Galveston (United States)
John A. Copland, Univ. of Texas Medical Branch at Galveston (United States)
Vsevolod L. Popov, Univ. of Texas Medical Branch at Galveston (United States)
Nicholas A. Kotov, Oklahoma State Univ. (United States)
Massoud Motamedi, Univ. of Texas Medical Branch at Galveston (United States)
Alexander A. Oraevsky, Fairway Medical Technologies Inc. (United States)

Published in SPIE Proceedings Vol. 4960:
Biomedical Optoacoustics IV
Alexander A. Oraevsky, Editor(s)

© SPIE. Terms of Use
Back to Top